- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00323414
Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver
Randomized Controlled Trial of Omega-3 Fatty Acids in the Treatment of Non-Alcoholic Steatohepatitis in Patients With Type 2 Diabetes Mellitus
Non-alcoholic steatohepatitis (NASH), the most severe form of liver injury in the spectrum of non-alcoholic fatty liver disease (NAFLD), has emerged as the major cause of chronic liver disease in developed countries. Among adults in the United States, the prevalence is between 5.7% and 17%. These rates are expected to increase concurrent with the epidemics of obesity and type 2 diabetes mellitus, which are the major risk factors for NAFLD and NASH. In addition to its high prevalence, NASH is also a progressive fibrotic disease that advances to cirrhosis and liver related death in 20% and 12% of patients, respectively. Among NASH patients with cirrhosis, 40% have liver related death. Diabetics are particularly prone to experience these poor outcomes. No therapy has been proven effective for patients with NASH.
The purpose of this study is to find out whether treatment with polyunsaturated fatty acids (eicosapentaenoic acid [EPA] combined with docosahexaenoic acid [DHA] called Opti-EPA) improves NASH compared to treatment with placebo pills. The placebo pills will contain corn oil and will be contained in a capsule, but have no medical effect on the body. The investigators will determine improvement in NASH from microscopic changes in the subject's liver tissue during 48 weeks of treatment. This means that the subject will need to have a liver biopsy before and after the treatment.
Omega-3 fatty acids are a form of polyunsaturated fats, one of the four basic types of fat that the body gets from food. (Cholesterol, saturated fat, and monounsaturated fat are the others.) One's body does not make this type of fat; it comes from food sources. These fats are found in foods like cold water fish (tuna, salmon, and mackerel), and vegetable products like flaxseed oil and walnuts.
Research shows that polyunsaturated fats are good for people. Studies have shown that it is good for heart health by playing a role in keeping blood cholesterol levels low, keeping irregular heart rhythms stable, and reducing blood pressure.
The drug being studied, Opti-EPA, is a nutritional supplement. They do not have to be reviewed by the Food and Drug Administration (FDA) like medicines do. Opti-EPA is considered experimental in this study. This means that the United States Food and Drug Administration (FDA) has not approved it for use in people with nonalcoholic fatty liver disease.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Although there is no proven effective treatment of NASH, dietary supplementation with long chain omega-3 polyunsaturated fatty acids (PUFA's) may be beneficial. This suggestion is based on three previously reported observations: first, patients with NASH consume less PUFAs and more saturated fats than subjects without NASH. Second, PUFAs are beneficial in patients with hypertension and hypertriglyceridemia. Third, PUFAs decrease lipid peroxidation and ameliorate hepatic steatosis in animal models of NAFLD.
We therefore hypothesize that the administration of these PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) will reduce hepatic fat content, inflammation and hepatic injury in patients with type 2 diabetes mellitus who have NASH.
Aims
To determine in patients with type 2 diabetes mellitus who have NASH if dietary supplementation with purified omega-3 fatty acids (EPA and DHA) will:
- Decrease the histologic severity of NASH.
- Alter the expression of genes important in the pathways of hepatic lipid synthesis and oxidation.
Study design:
Patients who meet the inclusion criteria will be randomized to receive omega-3 fatty acids or placebo. Stratified randomization will be done based on the NASH Clinical Research Network pathology score of 5.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44109
- MetroHealth Medical Center
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients (age >18 years)
- Have type 2 diabetes mellitus with good control of blood sugar (hemoglobin A1c [HbA1c] <7.5%) and will have been on a stable regimen of anti-diabetic agents for more than 4 months.
- NASH established on liver biopsy done within 6 months prior to inclusion in the study as determined by established histologic criteria
Exclusion Criteria:
- Cirrhosis of the liver
- End stage target organ damage in diabetes mellitus: advanced renal failure (serum creatinine > 2.0 mg/dl) with or without dialysis, severe neuropathy, or advanced peripheral vascular disease.
- Any organ dysfunction with anticipated life expectancy of less than 2 years
- Co-existent etiologies for liver disease
- Significant alcohol consumption, defined as more than 30 g per day in men and more than 20 g per day in women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Polyunsaturated fatty acid (Opti-EPA)
Polyunsaturated fatty acid will consist of purified EPA:DHA (360 mg EPA and 240 mg DHA) 6 gelcaps-3 capsules by mouth 2x per day x 48 weeks
|
Active experimental arm to patients with diabetes mellitus and non alcoholic steatohepatitis: Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)[360 mg EPA and 240 DHA in each capsule] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks
Other Names:
|
Placebo Comparator: Placebo
Gelcaps containing corn oil as placebo 6 capsules 3 capsules by mouth 2 x per day for 48 weeks
|
Placebo gelcaps containing corn oil identical to the PUFA gelcaps 6 capsules-3 capsules by mouth 2x per day x 48 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Improvement of >= 2 Points in NAFLD Activity Score (NAS)
Time Frame: 48 weeks
|
The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) is a score based on the liver biopsy.
It represents the sum of scores for steatosis, lobular inflammation, and ballooning, and ranges from 0-8, with high scores indicating more activity.
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Values
Time Frame: 48 weeks
|
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) measures insulin resistance, calculated by fasting insulin (μU/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405).
A higher score indicates higher insulin resistance.
|
48 weeks
|
Aspartate Amino Transferase (AST) Levels
Time Frame: 48 weeks
|
Aspartate amino transferase (IU/dL) at 48 weeks
|
48 weeks
|
Alanine Amino Transferase (ALT) Levels
Time Frame: 48 weeks
|
Alanine amino transferase (IU/dL) ay 48 weeks
|
48 weeks
|
Blood Glucose Levels
Time Frame: 48 weeks
|
Fasting blood glucose
|
48 weeks
|
HbA1C Levels
Time Frame: 48 weeks
|
Hemoglobin A1c
|
48 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Arthur J. McCullough, M.D., MetroHealth Medical Center
- Principal Investigator: Srinivasan Dasarathy, M.D., The Cleveland Clinic
Publications and helpful links
General Publications
- Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004 Mar;2(3):262-5. doi: 10.1016/s1542-3565(04)00014-x. Erratum In: Clin Gastroenterol Hepatol. 2004 Jun;2(6):522.
- Dasarathy S, Dasarathy J, Khiyami A, Yerian L, Hawkins C, Sargent R, McCullough AJ. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2015 Feb;49(2):137-44. doi: 10.1097/MCG.0000000000000099.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DK61732
- U01DK061732 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fatty Liver
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Hoffmann-La RocheCompletedFatty Liver, Non-alcoholic Fatty Liver Disease, NAFLDGermany, Austria
-
GenfitTerminatedNon-Alcoholic Fatty LiverNetherlands
-
Medical College of WisconsinENDRA Life Sciences, Inc.RecruitingFatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver DiseaseUnited States
-
Cairo UniversityRecruitingNon-Alcoholic Fatty Liver DiseaseEgypt
-
Miriam Vos, MDImmuron Ltd.; Advanced MR Analytics ABCompletedNonalcoholic Fatty Liver Disease (NAFLD)United States
-
Nehal Abou SeadaCompletedNon-Alcoholic Fatty Liver Disease
-
HaEmek Medical Center, IsraelTerminatedPatients With Fatty Liver DiseaseIsrael
-
AB Biotics, SACompletedNon Alcoholic Fatty LiverMexico
-
University of L'AquilaRecruitingNAFLD- Non Alcoholic Fatty Liver DiseaseItaly
Clinical Trials on Polyunsaturated fatty acid (Opti-EPA)
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedProteomics | Lipoprotein Metabolism | PCSK9United States
-
Mayo ClinicCompletedObesity | Barrett's EsophagusUnited States
-
Melvin McInnis, MDCompletedBipolar DisorderUnited States
-
Laval UniversityUniversity of Guelph; Advance Foods and Materials Network; Institut des Nutraceutiques... and other collaboratorsCompletedInsulin Resistance | Type 2 DiabetesCanada
-
VA Office of Research and DevelopmentUniversity of MarylandCompletedMetabolic SyndromeUnited States
-
Uppsala UniversityCompleted
-
Taipei City Psychiatric Center, TaiwanDepartment of Health, Executive Yuan, R.O.C. (Taiwan)Completed
-
Tokyo Medical UniversityUniversity of Toyama; China Medical University, Taiwan; Chiba University; Japan...CompletedDepression | PregnancyTaiwan, Japan
-
Joe ChanUniversity of Oslo; Ullevaal University Hospital; University Hospital of North... and other collaboratorsActive, not recruitingKidney TransplantationNorway
-
Medical University of ViennaNational Bank of AustriaCompletedMorbid Obesity | Adipose Tissue InflammationAustria